Eric W. Dittmann is a partner in the Litigation practice of Paul Hastings and is based in the firm’s New York office. Mr. Dittmann focuses his practice on life sciences patent litigation and post-grant proceedings. Mr. Dittmann has significant experience with a broad range of technologies in both the pharmaceutical and biotechnology fields. He has been recognized as a leading patent litigator by numerous publications, including The Legal 500, IAM Patent 1000, Benchmark Litigation, and LMG Life Sciences.
Paul Hastings Recognized in 2018 Managing Intellectual Property IP Stars
June 18, 2018
Paul Hastings Named Transatlantic IP Team of the Year by The American Lawyer
June 15, 2018
Paul Hastings Recognized in 2018 IAM Patent 1000 For Superb Track Record in Patent Litigation
June 15, 2018
Paul Hastings Wins Law360 Life Sciences Practice Group of the Year for 2017
February 05, 2018
Paul Hastings Scores Top Rankings in 2016 LMG Life Sciences
November 30, 2016
Generic Found to Infringe Valid Patent Claims Covering Helsinn’s Aloxi® Product
February 21, 2017
Federal Circuit Rejects Application of the On-Sale Bar to Contract Manufacturers
July 11, 2016
Federal Circuit Issues Expansive Ruling in Upholding Jurisdiction over Mylan in Delaware
March 18, 2016
Supreme Court Ruling in Alice v. CLS Bank Continues Framework for Patent Eligibility Set Forth in Mayo v. Prometheus
June 19, 2014
Today's Gilead Federal Circuit Decision Is a Significant Change to Double-Patenting Law
April 22, 2014
Federal Circuit Clarifies That Foreseeability Does Not Preclude the Application of the Doctrine of Equivalents
February 20, 2014
How Will H.R. 3309 (the Innovation Act) Impact Pharmaceutical and Biotechnology Patent Cases?
October 29, 2013
In an Issue of First Impression, the Federal Circuit Finds Infringement as a Matter of Law Despite a Sworn Certification Promising No Infringement
September 26, 2013
The Federal Circuit Further Clarifies The Obviousness-Type Double Patenting Doctrine For Composition Claims
August 27, 2012
Federal Circuit Reaffirms Patentability of Isolated DNA Molecules in View of Supreme Courts Mayo v. Prometheus Decision
August 17, 2012
Federal Circuit Signals Reigning in of Janssen and Rasmusson on Enablement/Utility
August 01, 2011
Failure to Launch
April 07, 2011
Second Circuit Cipro Decision Affirms No Per Se Antitrust Violation for Reverse-Payment Settlements, but Invites Petition for Rehearing En Banc
May 03, 2010
Patent Owner Protected by Safe Harbor Provision
January 27, 2010
Law360 Practice Group of the Year Awards for 2017: Life Sciences
Paul Hastings was named as a Practice Group of the Year in Life Sciences by Law360.
The article noted Paul Hastings’ undefeated track record in life sciences cases at the Patent Trial and Appeal Board, including victories on behalf of Acorda Therapeutics, which won four inter partes reviews against Kyle Bass’ Coalition for Affordable Drugs. Law360 also highlighted the representation of Galena Biopharma in a civil-only settlement resolving investigations regarding Galena’s past promotional practices for Abstral, a rapid onset opioid product.
The winners were chosen from nearly 750 submissions, and are recognized as "firms that racked up victories in litigation and closed the big deals to make their mark among clients and throughout the legal industry."
LMG Life Sciences Stars for 2017
Paul Hastings was recognized in the 2017 edition of LMG Life Sciences, with Highly Recommended rankings for General Patent Litigation and Hatch-Waxman Branded Litigation.
LMG Life Sciences selected seven individual lawyers as "Life Sciences Stars," including Joseph O’Malley, Bruce Wexler, Gerald Flattmann, Naveen Modi, Chad Peterman, Eric Dittmann, and Gary Giampetruzzi.
October 06, 2017
LMG Life Sciences Stars for 2016
Paul Hastings was recognized in the 2017 edition of LMG Life Sciences, with Highly Recommended rankings for General Patent Litigation and Hatch-Waxman Branded Litigation. LMG Life Sciences selected six individual lawyers as "Life Sciences Stars," including Joseph O’Malley, Bruce Wexler,
Gerald Flattmann, Gary Giampetruzzi, Naveen Modi, and Eric Dittmann.
November 30, 2016
2016 LMG Life Sciences Awards
Hastings was recognized with multiple LMG Life Sciences Awards. Bruce Wexler was named “General Patent
Litigator of the Year – New York” and Naveen Modi was recognized as “Post Grant
Proceedings Attorney of the Year.”
Life Sciences Patent Litigation practice also won awards for two Hatch-Waxman
Impact Cases of the Year, including Helsinn Healthcare SA et al. v. Teva
Pharmaceuticals USA Inc. et al., a win resolving a long-running patent dispute
over Aloxi®, a drug used to treat chemotherapy-induced nausea and vomiting. The
Paul Hastings team representing Helsinn was led by Joseph O’Malley. The firm
was also honored for its work on behalf of Eli Lily in Sanofi-Aventis US LLC et
al. v. Eli Lilly & Co., where Bruce Wexler led the team representing Eli
Lily in litigation regarding the marketing of Basaglar®, its insulin glargine
drug product. The case was settled in late 2015, with the press reporting Eli
Lilly’s ability to launch the drug
LMG Life Sciences Awards 2016
The Firm was shortlisted in four categories for the 2016 LMG Life Sciences Awards, which will be held on September 14 in New York.
Joseph O’Malley was nominated in the “Hatch-Waxman Litigator of the Year – Branded” category, Bruce Wexler was nominated in the “General Patent Litigator of the Year - New York” category, Naveen Modi was nominated in the “Post Grant Proceedings Attorney of the Year” category, and the Firm was nominated in the “Hatch-Waxman Litigation Firm of the Year – Branded” category.
Law360 Rising Star in Life Sciences
Eric Dittmann was recognized by Law360 as a rising star in its annual list of top attorneys in Life Sciences.
March 30, 2015
Legal Media Group's 2013 LMG Life Science Awards
The firm was nominated as a 2013 LMG Life Science nominee in the “Litigation Team of the Year” and “(General) Patent Litigation: Firm of the Year” categories.
August 12, 2013
Intellectual Property Magazine
Intellectual Property Magazine recognized Paul Hastings' IP Pharmaceutical Team as the Pharmaceutical Team of the Year.
November 30, 2010